NCT01121588 2025-01-23Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)PfizerPhase 1 Terminated44 enrolled 22 charts 1 FDA
NCT01945021 2021-02-21Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLCPfizerPhase 2 Completed129 enrolled 16 charts